歐洲多種癌症篩檢市場分析與預測：2023-2032

歐洲多種癌症篩檢市場規模預計將從 2023 年的 5.5 億美元成長到 2032 年的 20.9 億美元，預測期內複合年成長率為 15.93%。

液體活體組織切片檢測的使用不斷增加以及各種癌症類型的盛行率上升預計將推動多種癌症篩檢市場的成長。

歐洲多種癌症篩檢市場：簡介

由於人們對癌症早期檢測的認知不斷提高以及篩檢技術的進步，歐洲多種癌症篩檢市場正在經歷顯著成長。多癌篩檢提供了一種全面的方法來早期檢測各種癌症，從而改善治療結果並降低死亡率。此外，政府的支持措施、醫療保健政策以及對癌症研究和篩檢計畫的投資增加也正在推動市場擴張。此外，歐洲日益增加的癌症負擔和人口老化也凸顯了有效篩檢策略的必要性。以提高癌症診斷率和改善人口健康為重點，歐洲多種癌症篩檢市場有望持續成長和創新，從而塑造該地區的癌症治療格局。

本報告調查了歐洲多種癌症篩檢市場，並提供了市場概況、市場成長的各種影響因素分析、專利和研發趨勢、報銷方案、市場規模趨勢和預測，以及主要國家的詳細分析。主要企業等

目錄

執行摘要

第1章 市場

• 市場範圍
• 調查方法

第2章 市場概況

• 市場概況
• 多癌篩檢工作流程分析
• 市場足跡和成長潛力
• 未來性
• COVID-19 對市場的影響

第3章行業考察

• 專利分析
  • 專利申請趨勢
  • 專利分析（按國家）
  • 專利分析（按地區）
• 贖回場景
• 供應鏈分析
• 價格分析（按測試類型）

第4章市場動態

• 概述
• 影響分析
• 市場促進因素
  • 癌症的早期發現可以提高存活率並提供更好的治療
  • 由於液體活體組織切片的日益普及，篩檢變得更加容易
  • 透過早期發現癌症降低治療成本
• 市場挑戰
  • 對多種癌症篩檢測試缺乏認知
  • 預防性治療高成本
• 市場機會
  • 準備一系列強大的多種癌症篩檢測試以徹底改變癌症診斷
  • 定期發現新的生物標記

第5章多種癌症篩檢市場：按地區

• 概述
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他

第6章 公司簡介

• 價值鏈
• 活躍在生態系中的公司
• F. Hoffmann-La Roche Ltd

The Europe Multicancer Screening Market Expected to Reach $2.09 Billion by 2032

Introduction to Europe Multicancer Screening Market

The Europe multicancer screening market is projected to reach $2.09 billion by 2032 from $0.55 billion in 2023, growing at a CAGR of 15.93% during the forecast period 2023-2032. The multicancer screening market's growth is expected to be propelled by the heightened use of liquid biopsy testing and the escalating prevalence of various cancer types.

Market Introduction

The Europe Multicancer Screening Market is witnessing significant growth due to increasing awareness about early cancer detection and advances in screening technologies. Multicancer screening offers a comprehensive approach to detecting various cancers in their early stages, improving treatment outcomes and reducing mortality rates. Additionally, supportive government initiatives and healthcare policies, along with rising investments in cancer research and screening programs, are driving market expansion. Furthermore, the growing burden of cancer and aging population in Europe accentuates the need for effective screening strategies. With a focus on improving cancer diagnosis rates and enhancing population health, the Europe Multicancer Screening Market is poised for continued growth and innovation, shaping the landscape of cancer care in the region.

Market Segmentation:

Segmentation 1: by Country

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The key components in Europe multicancer screening are the kits and the related technologies for sample analysis. The advancements in new analysis methods like liquid biopsy are influencing the growth of this market. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for multicancer screening of various cancer types.

Competitive Strategy: The key players in the Europe multicancer screening market have been analyzed and profiled in the study, consisting of most product-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the Europe multicancer screening market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1 Markets

• 1.1 Market Scope
  • 1.1.1 Key Questions Answered in the Report
• 1.2 Research Methodology
  • 1.2.1 Multicancer Screening Market: Research Methodology
  • 1.2.2 Data Sources
  • 1.2.3 Market Estimation Model
  • 1.2.4 Criteria for Company Profiling

2 Market Overview

• 2.1 Market Overview
• 2.2 Multicancer Screening Workflow Analysis
• 2.3 Market Footprint and Growth Potential
• 2.4 Future Potential
• 2.5 COVID-19 Impact on the Market

3 Industry Insights

• 3.1 Patent Analysis
  • 3.1.1 Patent Filing Trend
  • 3.1.2 Patent Analysis (by Country)
  • 3.1.3 Patent Analysis (by Region)
• 3.2 Reimbursement Scenario
• 3.3 Supply Chain Analysis
• 3.4 Pricing Analysis (by Test Type)

4 Market Dynamics

• 4.1 Overview
• 4.2 Impact Analysis
• 4.3 Market Drivers
  • 4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
  • 4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
  • 4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
• 4.4 Market Challenges
  • 4.4.1 Lack of Awareness about the Multicancer Screening Tests
  • 4.4.2 Too Costly to be Used as Preventive Care
• 4.5 Market Opportunities
  • 4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
  • 4.5.2 New Biomarkers being Discovered Regularly

5 Multicancer Screening Regional Market, 2021-2032

• 5.1 Overview
• 5.2 Europe
  • 5.2.1 Germany
  • 5.2.2 France
  • 5.2.3 U.K.
  • 5.2.4 Italy
  • 5.2.5 Spain
  • 5.2.6 Rest-of-Europe

6 Company Profiles

• 6.1 Overview
• 6.2 Market Value Chain of Multicancer Screening Market
• 6.3 Multicancer Screening Ecosystem Active Players
• 6.4 F. Hoffmann-La Roche Ltd
  • 6.4.1 Company Overview
  • 6.4.2 Role of F. Hoffmann-La Roche Ltd in the Multicancer Screening Market
  • 6.4.3 Key Competitors of the Company
  • 6.4.4 Financials
  • 6.4.5 Corporate Strategies
  • 6.4.6 Business Strategies
  • 6.4.7 Analyst Perspective

List of Figures

• Figure 1: Europe Multicancer Screening Market, $Billion, 2022 and 2032
• Figure 2: Share of Multicancer Screening Market (by Region), 2022
• Figure 3: Multicancer Screening Market: Research Methodology
• Figure 4: Primary Research Methodology
• Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 6: Top-Down Approach (Segment-Wise Analysis)
• Figure 7: Multicancer Screening Workflow, End User Perspective
• Figure 8: Multicancer Screening Workflow, Laboratory Technician Perspective
• Figure 9: Europe Multicancer Screening Market, $Billion, 2021-2032
• Figure 10: COVID-19 Impact
• Figure 11: Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
• Figure 12: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
• Figure 13: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
• Figure 14: Supply Chain Analysis of the Multicancer Screening Market
• Figure 15: Multicancer Screening Market Dynamics
• Figure 16: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
• Figure 17: Liquid Biopsy vs. Tissue Biopsy
• Figure 18: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
• Figure 19: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
• Figure 20: Lead-Time Bias in Cancer Screening
• Figure 21: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
• Figure 22: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
• Figure 23: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
• Figure 24: Multicancer Screening Market (by Region), $Billion, 2021-2032
• Figure 25: Europe Multicancer Screening Market, $Billion, 2021-2032
• Figure 26: Europe Multicancer Screening Market (by Country), $Million, 2021-2032
• Figure 27: Germany Multicancer Screening Market, $Million, 2021-2032
• Figure 28: France Multicancer Screening Market, $Million, 2021-2032
• Figure 29: U.K. Multicancer Screening Market, $Million, 2021-2032
• Figure 30: Italy Multicancer Screening Market, $Million, 2021-2032
• Figure 31: Spain Multicancer Screening Market, $Million, 2021-2032
• Figure 32: Rest-of-Europe Multicancer Screening Market, $Million, 2021-2032
• Figure 33: Multicancer Screening Market, Total Number of Companies Profiled
• Figure 34: Multicancer Screening Market: Value Chain
• Figure 35: F. Hoffmann-La Roche Ltd: Product Portfolio
• Figure 36: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
• Figure 37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
• Figure 38: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022

List of Tables

• Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Multicancer Screening Market
• Table 2: Technological Trends in Multicancer Screening Market
• Table 3: Average Prices of Multicancer Screening Kits Calculation
• Table 4: Likert Scale
• Table 5: Impact Analysis of Market Drivers
• Table 6: Impact Analysis of Market Challenges
• Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
• Table 8: Top Multicancer Screening Tests and Their Costs ($)
• Table 9: Multicancer Screening Market, Pipeline Tests
• Table 10: Cancers and Their Most Common Biomarker Tests